Lyra Therapeutics Inc is a biotechnology business based in the US. Lyra Therapeutics Inc shares (LYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.18 – a decrease of 1.11% over the previous week. Lyra Therapeutics Inc employs 88 staff and has a trailing 12-month revenue of around $1.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.18 |
|---|---|
| 52-week range | $0.17 - $6.79 |
| 50-day moving average | $0.26 |
| 200-day moving average | $1.96 |
| Wall St. target price | $1.25 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.42 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.178 from 2024-11-20
| 1 week (2024-11-15) | 4.71% |
|---|---|
| 1 month (2024-10-22) | -29.37% |
| 3 months (2024-08-22) | -42.88% |
| 6 months (2024-05-22) | -48.00% |
| 1 year (2023-11-22) | -94.22% |
|---|---|
| 2 years (2022-11-22) | -95.45% |
| 3 years (2021-11-22) | 5.37 |
| 5 years (2019-11-18) | N/A |
| Revenue TTM | $1.5 million |
|---|---|
| Gross profit TTM | $-34,234,000 |
| Return on assets TTM | -42.29% |
| Return on equity TTM | -186.18% |
| Profit margin | 0% |
| Book value | $0.32 |
| Market Capitalization | $11.8 million |
TTM: trailing 12 months
We're not expecting Lyra Therapeutics Inc to pay a dividend over the next 12 months.
Over the last 12 months, Lyra Therapeutics Inc's shares have ranged in value from as little as $0.165 up to $6.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lyra Therapeutics Inc's is -0.036. This would suggest that Lyra Therapeutics Inc's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Lyra Therapeutics Inc has bucked the trend.
Lyra Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.